References
- Revlimid (lenalidomide) [package insert]. Summit, NJ: Celgene Corporation; 2017.
- Castaneda CP, Zeldis JB, Freeman J, et al. RevAssist: a comprehensive risk minimization programme for preventing fetal exposure to lenalidomide. Drug Saf. 2008;31:743–752.
- Bwire R, Freeman J, Houn F. Managing the teratogenic risk of thalidomide and lenalidomide: an industry perspective. Expert Opin Drug Saf. 2011;10:3–8.
- Braunstein GD. False-positive serum human chorionic gonadotropin results: causes, characteristics, and recognition. Am J Obstet Gynecol. 2002;187:217–224.
- Stenman UH, Alfthan H, Hotakainen K. Human chorionic gonadotropin in cancer. Clin Biochem. 2004;37:549–561.
- Tageja N, Valent J, Giorgadze T, et al. Positive pregnancy tests in a postmenopausal woman due to beta-human chorionic gonadotropin production by multiple myeloma. Am J Med Sci. 2010;339:182–184.
- Slone SP, Ahmed Z, Cole LA, et al. Positive pregnancy tests in a nongravid, premenopausal woman due to hCG beta-chain production by multiple myeloma. Am J Clin Pathol. 2005;124:108–112.
- Uhl K, Cox E, Rogan R, et al. Thalidomide use in the US: experience with pregnancy testing in the S.T.E.P.S. programme. Drug Saf. 2006;29:321–329.